SRX3177

SRX3177 is a triple inhibitor of CDK4/6, PI3K, and BRD4, with IC50s of E protein and the BRD2/4 BD1 domain, restores E protein-attenuated NF-κB activity. SRX3177 exerts broad cytotoxic activity against cancer cells. SRX3177 can be used for the study of anti-SARS-CoV-2 and cancer[1][2].

Product Specifications

CAS Number

[2241237-51-2]

UNSPSC

12352005

Target

CDK; Epigenetic Reader Domain; NF-κB; PI3K; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Epigenetics; NF-κB; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Inflammation/Immunology; Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/srx3177.html

Purity

99.59

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1C=C(N2CCOCC2)OC3=C1SC=C3C4=CC=C(NC5=NC6=C(C=C(N6C7CCCC7)C(N(C)C)=O)C=N5)C=C4

Molecular Formula

C31H32N6O4S

Molecular Weight

584.69

References & Citations

[1]Burgoyne AM, et al. A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity. Cell Discov. 2020 Jul 28;6 (1) :49.|[2]Pandey K, et al. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2. Antiviral Res. 2024 Jul;227:105904.